Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314. “This is a significant milestone for our efforts to ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management ...